Compare Apollo Global Management Ord Shs (APO) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs DexCom, Inc. — how do they compare? Apollo Global Management Ord Shs trades at $138.13 (market cap $82.84B), while DexCom, Inc. trades at $90.64 (market cap $33.79B). The key difference: Apollo Global Management Ord Shs is far larger — about 2.5× DexCom, Inc.'s market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| APO | DXCM | |
|---|---|---|
Market Cap | $82.84B | $33.79B |
Sector | Financials | Health |
52-Week High | $152.70 | $89.53 |
52-Week Low | $100.30 | $54.84 |
Enterprise Value | -$168.65B | $33.24B |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $138.79, up 5.13% today, near its 52-week high. The stock shows a bullish technical trend with strong analyst support, including 23 buy ratings and a consensus price target of $151.50. Recent Q2 2026 earnings of $2.11 per share missed estimates, but revenue growth and record assets under management of $1.05 trillion highlight operational strength. The company continues expanding in AI infrastructure deals, as noted in recent news.
Outlook remains positive given robust fundraising and perpetual capital growth, though risks include expense pressures and market volatility. The high P/E ratio of 49.92 suggests premium valuation, requiring sustained earnings growth to justify upside. Investors should weigh strong institutional sentiment against execution risks in a competitive asset management landscape.
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
